<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:hpo ids='HP_0000855'>Insulin resistance</z:hpo>, which manifests itself as endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> overproduction and reduced insulin-mediated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake, is a core defect in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> and the peroxisome proliferator-activated receptor-gamma <z:chebi fb="4" ids="48705">agonists</z:chebi>, the <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZDs), both lower <z:chebi fb="105" ids="17234">glucose</z:chebi>, although their mechanism of action is still subject to debate </plain></SENT>
<SENT sid="2" pm="."><plain>This review analyses the evidence relevant to these mechanisms in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: A systematic search of MEDLINE identified a total of 42 clinical studies that investigated the effects of TZDs (n=23) and/or <z:chebi fb="0" ids="6801">metformin</z:chebi> (n=19) on endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (using tracer <z:chebi fb="105" ids="17234">glucose</z:chebi> techniques) and peripheral <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal (using the euglycaemic-hyperinsulinaemic clamp) in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n=549) </plain></SENT>
<SENT sid="4" pm="."><plain>The original variables assessed were converted into standardised units and their mean group values were listed separately for open and placebo-controlled studies </plain></SENT>
<SENT sid="5" pm="."><plain>Statistical analysis was scarried out, treating mean group values as individual values and comparing results (both as absolute values and percentage changes from baseline) across study categories (open vs placebo-controlled, TZDs vs <z:chebi fb="0" ids="6801">metformin</z:chebi>) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Both TZDs and <z:chebi fb="0" ids="6801">metformin</z:chebi> enhance insulin suppression of endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production and fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> clearance </plain></SENT>
<SENT sid="7" pm="."><plain>TZDs, but not <z:chebi fb="0" ids="6801">metformin</z:chebi>, also improve insulin-mediated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake at <z:hpo ids='HP_0000001'>all</z:hpo> insulin levels </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:chebi fb="0" ids="6801">metformin</z:chebi> improves fasting hepatic insulin sensitivity and <z:chebi fb="105" ids="17234">glucose</z:chebi> clearance; TZDs improve fasting hepatic insulin sensitivity and <z:chebi fb="105" ids="17234">glucose</z:chebi> clearance, and potentiate <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal under insulinised conditions </plain></SENT>
</text></document>